Edaravone: meta-analysis of COVID-19 studies

All studies Mortality Ventilation ICU Serious outcomes RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−50%

Mortality (1)−50%

Ventilation (1)75%

ICU admission (1)−10%

RCTs (1)−50%

Late (1)−50%

00.511.5+

← Edaravone
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Edaravone COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Moslemi (RCT)−50%1.50 · 0.28–7.99death3/192/19ICU patients

Late treatment−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.65

All studies−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6500.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Moslemi (RCT)−50%1.50 · 0.28–7.993/192/19ICU patients

Late treatment−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.65

All studies−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6500.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Moslemi (RCT)75%0.25 · 0.06–1.032/198/19ICU patients

Late treatment75%0.25 · 0.06–1.032/198/1975% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.054

All studies75%0.25 · 0.06–1.032/198/1975% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.05400.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Moslemi (RCT)−10%1.10 · 0.21–5.7219 (n)19 (n)ICU patients

Late treatment−10%1.10 · 0.21–5.7219 (n)19 (n)10% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.92

All studies−10%1.10 · 0.21–5.7219 (n)19 (n)10% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.9200.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Moslemi (RCT)−50%1.50 · 0.28–7.99death3/192/19ICU patients

Late treatment−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.65

All studies−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6500.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Moslemi (RCT)−50%1.50 · 0.28–7.99death3/192/19ICU patients

Late treatment−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.65

All studies−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6500.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Moslemi (RCT)−50%1.50 · 0.28–7.993/192/19ICU patients

Late treatment−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.65

All studies−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6500.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Moslemi (RCT)−50%1.50 · 0.28–7.99death3/192/19ICU patients

Late treatment−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.65

All studies−50%1.50 · 0.28–7.993/192/1950% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6500.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →

c19early.org

October 2026

Edaravone COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Moslemi (RCT)−50%1.50 · 0.28–7.99death3/192/19ICU patients Moslemi (RCT)75%0.25 · 0.06–1.03ventilation2/198/19ICU patients Moslemi (RCT)−10%1.10 · 0.21–5.72ICU19 (n)19 (n)ICU patients

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Edaravone
reduces riskEdaravone
increases risk →